<p>Corient Private Wealth LLC 在最近向证券交易委员会提交的文件中表示，在第二季度将其在 Moderna, Inc.（NASDAQ:MRNA - 免费报告）股票中的持股比例提高了 155.8%。该基金在季度内额外购买了 34,354 股后，持有 56,400 股公司的股票。截至其最近的 SEC 文件，Corient Private Wealth LLC 在 Moderna 的持股价值为 1,537,000 美元。</p>
<ul>
<li>Moderna 股票看起来适合进行空头挤压</li>
</ul>
<p>其他几家对冲基金和机构投资者最近也增加或减少了对 MRNA 的持股。Osaic Holdings Inc.在第二季度将其在 Moderna 的持股增加了 7.0%。Osaic Holdings Inc.现在拥有 46,709 股公司的股票，价值 1,289,000 美元，此前在上个季度又购买了 3,065 股。Thrivent Financial for Lutherans 在第二季度将其在 Moderna 的持股提高了 600.7%。Thrivent Financial for Lutherans 现在拥有 92,999 股公司的股票，价值 2,566,000 美元，此前在上个季度又购买了 79,726 股。Marex Group plc 在第二季度获得了 Moderna 的新股份，价值 359,000 美元。怀俄明州也在第二季度获得了 Moderna 的新股份，价值 94,000 美元。最后，Hudson Bay Capital Management LP 在第二季度将其在 Moderna 的持股提高了 108.4%。Hudson Bay Capital Management LP 现在拥有 75,000 股公司的股票，价值 2,069,000 美元，此前在上个季度又购买了 39,020 股。机构投资者和对冲基金持有公司 75.33% 的股票。</p>
<h2>Moderna 股票表现</h2>
<p>NASDAQ MRNA 的股票在周四开盘价为 32.73 美元。该股票的市值为 127.9 亿美元，市盈率为-4.06，贝塔值为 1.11。Moderna, Inc.的 52 周低点为 22.28 美元，52 周高点为 48.92 美元。该股票的 50 日移动平均价格为 26.78 美元，200 日移动平均价格为 27.33 美元。</p>
<ul>
<li>MarketBeat 周回顾 – 03/10 - 03/14</li>
</ul>
<p>Moderna（NASDAQ:MRNA - 获取免费报告）最近在 11 月 6 日（星期四）发布了季度财报。公司报告季度每股收益（EPS）为（0.51 美元），超出分析师一致预期的（2.15 美元）1.64 美元。Moderna 的股本回报率为-29.81%，净利润率为-139.61%。该业务在季度内的收入为 10.2 亿美元，而分析师预期为 8.9329 亿美元。去年同期，公司每股收益为 0.03 美元。Moderna 的季度收入同比下降了 45.4%。作为一个整体，研究分析师预测 Moderna, Inc.在当前年度将发布-9.61 的每股收益。</p>
<h2>Moderna 的内部买卖</h2>
<p>在其他新闻中，董事 Noubar Afeyan 在 12 月 11 日（星期四）以 29.48 美元的平均价格出售了 23,853 股股票，总价值为 703,186.44 美元。交易完成后，该董事持有 3,924 股公司的股票，价值约 115,679.52 美元。这代表了他们持股比例的 85.87% 的减少。该交易已在向证券交易委员会的法律文件中披露，可以通过 SEC 网站访问。目前 10.90% 的股票由公司内部人士持有。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>Moderna：首席执行官刚刚购买 500 万美元股票的 4 个关键原因</li>
</ul>
<p>几家研究公司最近对 MRNA 发布了报告。Weiss Ratings 在 10 月 8 日（星期三）重申了对 Moderna 股票的 “卖出（e+）” 评级。Leerink Partners 将 Moderna 的目标价格从 15.00 美元上调至 18.00 美元，并在 11 月 21 日（星期五）的研究报告中给予公司 “表现不佳” 的评级。花旗集团将 Moderna 的目标价格从 30.00 美元下调至 28.00 美元，并在 10 月 23 日（星期四）的研究报告中为公司设定了 “中性” 评级。摩根士丹利在 12 月 12 日（星期五）的报告中将 Moderna 的目标价格从 30.00 美元下调至 28.00 美元，并对该股票设定了 “同等权重” 的评级。最后，Needham &amp; Company LLC 在 10 月 20 日（星期一）的研究报告中重申了对 Moderna 的 “持有” 评级。两位分析师对该股票给予了买入评级，十二位分析师给予了持有评级，五位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “减持”，平均目标价格为 29.21 美元。</p>
<p><strong>获取我们对 Moderna 的最新分析</strong></p>
<h2>Moderna 公司简介</h2>
<p>（免费报告）</p>
<p>Moderna, Inc.是一家总部位于马萨诸塞州剑桥的生物技术公司，专注于信使 RNA（mRNA）治疗和疫苗。该公司的平台利用合成 mRNA 指示细胞产生可以预防或治疗疾病的蛋白质。自 2010 年成立以来，Moderna 已从早期研究发展到一系列旨在应对传染病、罕见遗传疾病和慢性疾病的疫苗和治疗候选产品。</p>
<p>Moderna 的旗舰产品是其基于 mRNA 的 COVID-19 疫苗，这是首个获得紧急使用授权并在多个司法管辖区获得完全批准的疫苗。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过 Moderna</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
<li>任何费用可以从资本利得税中扣除吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘记 AI，这将是下一个重大科技突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJOQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJOQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Moderna 吗？</h2>
<p>在你考虑 Moderna 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Moderna 并不在名单上。</p>
<p>虽然 Moderna 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MRNA

<p>Corient Private Wealth LLC 在第二季度将其在 Moderna, Inc. 的持股增加了 155.8%，目前持有 56,400 股，价值 154 万美元。分析师对 Moderna 的评级褒贬不一，普遍评级为 “减持”，平均目标价为 29.21 美元。机构投资者持有该股票的 75.33%，最近的内部交易包括董事 Noubar Afeyan 的一笔重大出售</p>

<p>Corient Private Wealth LLC boosted its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 155.8% during the second quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The fund owned 56,400 shares of the company's stock after acquiring an additional 34,354 shares during the quarter. Corient Private Wealth LLC's holdings in Moderna were worth $1,537,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Corient Private Wealth LLC 在最近向证券交易委员会提交的文件中表示，在第二季度将其在 Moderna, Inc.（NASDAQ:MRNA - 免费报告）股票中的持股比例提高了 155.8%。该基金在季度内额外购买了 34,354 股后，持有 56,400 股公司的股票。截至其最近的 SEC 文件，Corient Private Wealth LLC 在 Moderna 的持股价值为 1,537,000 美元。</p>
</div><ul>
<li>Moderna Stock Looks Ripe for a Short Squeeze</li>
</ul>
<div class="lb-trans"><ul>
<li>Moderna 股票看起来适合进行空头挤压</li>
</ul>
</div><p>Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MRNA. Osaic Holdings Inc. increased its holdings in shares of Moderna by 7.0% in the second quarter. Osaic Holdings Inc. now owns 46,709 shares of the company's stock valued at $1,289,000 after purchasing an additional 3,065 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in Moderna by 600.7% in the 2nd quarter. Thrivent Financial for Lutherans now owns 92,999 shares of the company's stock valued at $2,566,000 after buying an additional 79,726 shares during the last quarter. Marex Group plc acquired a new stake in shares of Moderna in the 2nd quarter valued at $359,000. State of Wyoming acquired a new stake in shares of Moderna in the 2nd quarter valued at $94,000. Finally, Hudson Bay Capital Management LP raised its position in shares of Moderna by 108.4% during the second quarter. Hudson Bay Capital Management LP now owns 75,000 shares of the company's stock worth $2,069,000 after acquiring an additional 39,020 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也增加或减少了对 MRNA 的持股。Osaic Holdings Inc.在第二季度将其在 Moderna 的持股增加了 7.0%。Osaic Holdings Inc.现在拥有 46,709 股公司的股票，价值 1,289,000 美元，此前在上个季度又购买了 3,065 股。Thrivent Financial for Lutherans 在第二季度将其在 Moderna 的持股提高了 600.7%。Thrivent Financial for Lutherans 现在拥有 92,999 股公司的股票，价值 2,566,000 美元，此前在上个季度又购买了 79,726 股。Marex Group plc 在第二季度获得了 Moderna 的新股份，价值 359,000 美元。怀俄明州也在第二季度获得了 Moderna 的新股份，价值 94,000 美元。最后，Hudson Bay Capital Management LP 在第二季度将其在 Moderna 的持股提高了 108.4%。Hudson Bay Capital Management LP 现在拥有 75,000 股公司的股票，价值 2,069,000 美元，此前在上个季度又购买了 39,020 股。机构投资者和对冲基金持有公司 75.33% 的股票。</p>
</div><h2>Moderna Stock Performance</h2>
<div class="lb-trans"><h2>Moderna 股票表现</h2>
</div><p>Shares of NASDAQ MRNA opened at $32.73 on Thursday. The stock has a market capitalization of $12.79 billion, a PE ratio of -4.06 and a beta of 1.11. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $48.92. The stock has a 50 day moving average price of $26.78 and a 200 day moving average price of $27.33.</p>
<div class="lb-trans"><p>NASDAQ MRNA 的股票在周四开盘价为 32.73 美元。该股票的市值为 127.9 亿美元，市盈率为-4.06，贝塔值为 1.11。Moderna, Inc.的 52 周低点为 22.28 美元，52 周高点为 48.92 美元。该股票的 50 日移动平均价格为 26.78 美元，200 日移动平均价格为 27.33 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 03/10 - 03/14</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 03/10 - 03/14</li>
</ul>
</div><p>Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($2.15) by $1.64. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The business had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $893.29 million. During the same quarter last year, the company posted $0.03 earnings per share. Moderna's quarterly revenue was down 45.4% on a year-over-year basis. As a group, research analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.</p>
<div class="lb-trans"><p>Moderna（NASDAQ:MRNA - 获取免费报告）最近在 11 月 6 日（星期四）发布了季度财报。公司报告季度每股收益（EPS）为（0.51 美元），超出分析师一致预期的（2.15 美元）1.64 美元。Moderna 的股本回报率为-29.81%，净利润率为-139.61%。该业务在季度内的收入为 10.2 亿美元，而分析师预期为 8.9329 亿美元。去年同期，公司每股收益为 0.03 美元。Moderna 的季度收入同比下降了 45.4%。作为一个整体，研究分析师预测 Moderna, Inc.在当前年度将发布-9.61 的每股收益。</p>
</div><h2>Insider Buying and Selling at Moderna</h2>
<div class="lb-trans"><h2>Moderna 的内部买卖</h2>
</div><p>In other news, Director Noubar Afeyan sold 23,853 shares of the stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $29.48, for a total value of $703,186.44. Following the completion of the transaction, the director owned 3,924 shares of the company's stock, valued at approximately $115,679.52. This represents a 85.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. 10.90% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Noubar Afeyan 在 12 月 11 日（星期四）以 29.48 美元的平均价格出售了 23,853 股股票，总价值为 703,186.44 美元。交易完成后，该董事持有 3,924 股公司的股票，价值约 115,679.52 美元。这代表了他们持股比例的 85.87% 的减少。该交易已在向证券交易委员会的法律文件中披露，可以通过 SEC 网站访问。目前 10.90% 的股票由公司内部人士持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares</li>
</ul>
<div class="lb-trans"><ul>
<li>Moderna：首席执行官刚刚购买 500 万美元股票的 4 个关键原因</li>
</ul>
</div><p>Several research firms recently issued reports on MRNA. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of Moderna in a report on Wednesday, October 8th. Leerink Partners upped their target price on shares of Moderna from $15.00 to $18.00 and gave the company an &#34;underperform&#34; rating in a research report on Friday, November 21st. Citigroup lowered their price target on shares of Moderna from $30.00 to $28.00 and set a &#34;neutral&#34; rating for the company in a research report on Thursday, October 23rd. Morgan Stanley cut their price objective on shares of Moderna from $30.00 to $28.00 and set an &#34;equal weight&#34; rating on the stock in a report on Friday, December 12th. Finally, Needham &amp; Company LLC reaffirmed a &#34;hold&#34; rating on shares of Moderna in a research note on Monday, October 20th. Two analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of &#34;Reduce&#34; and an average target price of $29.21.</p>
<div class="lb-trans"><p>几家研究公司最近对 MRNA 发布了报告。Weiss Ratings 在 10 月 8 日（星期三）重申了对 Moderna 股票的 “卖出（e+）” 评级。Leerink Partners 将 Moderna 的目标价格从 15.00 美元上调至 18.00 美元，并在 11 月 21 日（星期五）的研究报告中给予公司 “表现不佳” 的评级。花旗集团将 Moderna 的目标价格从 30.00 美元下调至 28.00 美元，并在 10 月 23 日（星期四）的研究报告中为公司设定了 “中性” 评级。摩根士丹利在 12 月 12 日（星期五）的报告中将 Moderna 的目标价格从 30.00 美元下调至 28.00 美元，并对该股票设定了 “同等权重” 的评级。最后，Needham &amp; Company LLC 在 10 月 20 日（星期一）的研究报告中重申了对 Moderna 的 “持有” 评级。两位分析师对该股票给予了买入评级，十二位分析师给予了持有评级，五位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “减持”，平均目标价格为 29.21 美元。</p>
</div><p><strong>Get Our Latest Analysis on Moderna</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Moderna 的最新分析</strong></p>
</div><h2>Moderna Company Profile</h2>
<div class="lb-trans"><h2>Moderna 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company's platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.</p>
<div class="lb-trans"><p>Moderna, Inc.是一家总部位于马萨诸塞州剑桥的生物技术公司，专注于信使 RNA（mRNA）治疗和疫苗。该公司的平台利用合成 mRNA 指示细胞产生可以预防或治疗疾病的蛋白质。自 2010 年成立以来，Moderna 已从早期研究发展到一系列旨在应对传染病、罕见遗传疾病和慢性疾病的疫苗和治疗候选产品。</p>
</div><p>Moderna's flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.</p>
<div class="lb-trans"><p>Moderna 的旗舰产品是其基于 mRNA 的 COVID-19 疫苗，这是首个获得紧急使用授权并在多个司法管辖区获得完全批准的疫苗。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Moderna</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Moderna</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
<li>任何费用可以从资本利得税中扣除吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘记 AI，这将是下一个重大科技突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJOQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=MRNA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Moderna Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Moderna 吗？</h2>
</div><p>Before you consider Moderna, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Moderna 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Moderna 并不在名单上。</p>
</div><p>While Moderna currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Moderna 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Corient Private Wealth LLC 持有 Moderna 公司价值 154 万美元的股票